Aegle Therapeutics: Funding, Investors & Team (Sep 2026)
Aegle Therapeutics is a privately-held biotechnology company developing a first in class therapy using extracellular vesicles, including exosomes, secreted by allogeneic bone marrow-derived mesenchymal stem cells. Aegle's platform technology is initially being developed to treat dystrophic epidermolysis bullosa, a rare pediatric skin blistering disorder. Aegle's IND for DEB has been cleared by the FDA and the company expects to enter the clinic by the 2H of 2020. Its proprietary platform isolation technology is cell-free and has the potential to demonstrate a safer, lower-cost means of harnessing the regenerative healing power of stem cells without using the cells. Aegle believes its EV therapy has the potential for functional regeneration and organization of complex tissue structures that can enhance healing, reduce scarring, minimize contraction, and improve overall cosmesis. The company was founded in 2013 and is based in Miami, Florida.
Aegle Therapeutics has raised $460k across 1 funding round on record, the most recent an undisclosed round of $460k announced in Mar 2026.
That round is below the $8.0M median round size for Biotechnology companies tracked on FundedIQ over the last two years.
Aegle Therapeutics Company Profile and Key Stats
Latest funding round on record: Mar 2026.
Aegle Therapeutics Funding Rounds
Aegle Therapeutics Founders and Leadership Team
Contact details for the Aegle Therapeutics team: 1 has a LinkedIn profile.
Start 14-day free trial →Aegle Therapeutics Funding Compared to Other Biotechnology Startups
Aegle Therapeutics' latest round of $460k is below the median round in Biotechnology. Medians cover the last 24 months of disclosed rounds.
Funded Startups Like Aegle Therapeutics in Biotechnology and Miami
Companies Similar to Aegle Therapeutics
SeqWell’s is a biotechnology company that specializes in the fields of gene sequencing and laboratory…
DermaSensor’s mission is to save lives and healthcare costs by providing easy access to effective skin cancer…
Solstice Oncology is a clinical stage immuno-oncology company
Encoded Therapeutics is a developer of precision gene therapies intended to provide treatment for a broad…
BrainChild Bio is a biotechnology company in the clinical stage that specializes in pediatric brain tumors.…
Superluminal Medicines is a biotech company that specializes in rapidly developing new drugs through a…
Senticell's mission is to fully harness the unique immune and genetic functions of RBC to transform and treat…
ImmunoPhotonics, Inc. develops immunotherapy-based treatments for cancer. ImmunoPhotonics, Inc. has a…
EIT Pharma is a commercial-stage biotechnology company focuses on developing and commercializing…
Halia Therapeutics is a biopharmaceutical company in the preclinical stage that is developing new treatments…
Noveome Biotherapeutics, Inc. is an advanced biopharmaceutical company that focuses on groundbreaking…
XiltriX North America is an information technology company that specializes in monitoring, predictive…
Aegle Therapeutics Funding FAQs
What does Aegle Therapeutics do?
Aegle Therapeutics is a privately-held biotechnology company developing a first in class therapy using extracellular vesicles, including exosomes, secreted by allogeneic bone marrow-derived mesenchymal stem cells. Aegle's platform technology is initially being developed to treat dystrophic epidermolysis bullosa, a rare pediatric skin blistering disorder. Aegle's IND for DEB has been cleared by the FDA and the company expects to enter the clinic by the 2H of 2020. Its proprietary platform isolation technology is cell-free and has the potential to demonstrate a safer, lower-cost means of harnessing the regenerative healing power of stem cells without using the cells. Aegle believes its EV therapy has the potential for functional regeneration and organization of complex tissue structures that can enhance healing, reduce scarring, minimize contraction, and improve overall cosmesis. The company was founded in 2013 and is based in Miami, Florida.
How much funding has Aegle Therapeutics raised?
Aegle Therapeutics has raised $460k across 1 round on record. The most recent is an undisclosed round of $460k announced in Mar 2026.
When did Aegle Therapeutics last raise funding?
Aegle Therapeutics' most recent funding round on record is an undisclosed round of $460k, announced in Mar 2026.
Who founded Aegle Therapeutics?
FundedIQ lists Shelley A Hartman (Founder) at Aegle Therapeutics.
Where is Aegle Therapeutics headquartered?
Aegle Therapeutics is based in Miami, Florida, United States.
How many employees does Aegle Therapeutics have?
Aegle Therapeutics is in the 1-10 employee band.
How does Aegle Therapeutics' funding compare to other Biotechnology startups?
Aegle Therapeutics' latest round of $460k is below the $8.0M median round size for Biotechnology companies on FundedIQ across 4,183 tracked companies over the last two years.
About FundedIQ's Aegle Therapeutics Funding Data
FundedIQ tracks announced funding rounds and refreshes this profile every week. Round dates, stages and amounts are normalised to a single format, converted to US dollars, and de-duplicated: two records of the same round announced days apart are merged, and two genuinely different rounds are kept apart on the amounts they disclose. Amounts shown are the disclosed figures only — a round announced without a number is listed and excluded from the total rather than estimated.
Employee counts are reported bands, not exact headcounts. Founder and executive names carry the job title on record. Anything we do not hold for Aegle Therapeutics is left off this page rather than filled in.
Know who just raised. Then know who to reach.
Every newly funded startup with its round, its investors and its founders: delivered weekly by email, or searchable in the app.
Alerts from $19/mo · Pro from $99/mo. Card required, nothing charged until day 15, and we email you 3 days before that.